Phase II Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer
Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer.
Phase II Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer (En español)
Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer. (En español)